2021
DOI: 10.1111/bjd.19889
|View full text |Cite
|
Sign up to set email alerts
|

Identifying gaps in global health dermatology: a survey of GLODERM members

Abstract: therapy without rituximab (15% vs. 37%). 8 Taking the evidence together, rituximab can improve not only the overall survival but also the 1-year survival of patients with BP despite its risk of severe infections.Our data suggest that rituximab improves overall survival and may have a low rate of infectious complications compared with conventional therapy. A prospective randomized clinical trial is needed to validate our observations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
references
References 4 publications
(5 reference statements)
0
0
0
Order By: Relevance